SCHEMBL10114287

SCHEMBL10114287

CCC(C)(C)S(=O)(=O)NC1CCC(C(=O)Nc2ccc3c(=O)c4ccccc4oc3c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 8/20 0.60
▸ MEN1 O00255 7/20 0.60
▸ KMT2A Q03164 7/20 0.60
▸ NPC1 O15118 6/20 0.60
▸ RAB9A P51151 6/20 0.60
▸ GAA P10253 3/20 0.60
▸ LMNA P02545 2/20 0.60
▸ HTT P42858 2/20 0.60
▸ KDM4E B2RXH2 5/20 0.46
▸ ALDH1A1 P00352 5/20 0.46
▸ NPSR1 Q6W5P4 3/20 0.44
▸ HSD17B10 Q99714 3/20 0.42
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MAPT P10636 4/20 0.41
▸ POLB P06746 2/20 0.41
▸ ERAP1 Q9NZ08 1/20 0.41
▸ TSHR P16473 2/20 0.40
▸ DHODH Q02127 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114279 0.90 SMN1; SMN2 (0.57) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL13565039 0.84 NPC1 (0.46) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL13203715 0.76 KDM4E (0.70) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL10113096 0.76 KDM4E (0.70) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL10114848 0.75 NPC1 (0.53) SMN1; SMN2KMT2ANPC1RAB9ALMNA
SCHEMBL14424368 0.75 NPC1 (0.53) SMN1; SMN2KMT2ANPC1RAB9ALMNA
SCHEMBL10114879 0.74 NPY5R (0.58) MEN1KMT2AGAAKDM4ENPSR1
SCHEMBL14424375 0.74 NPY5R (0.58) MEN1KMT2AGAAKDM4ENPSR1
SCHEMBL17090164 0.74 CNR2 (0.39) SMN1; SMN2MEN1KMT2ANPC1RAB9A
SCHEMBL10114264 0.72 MEN1 (0.45) MEN1KMT2ANPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R SMN1; SMN2 2213/4885MEN1 2876/4885KMT2A 2912/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885MEN1 2932/4885KMT2A 2768/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885MEN1 2926/4885KMT2A 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback